• No image available for this medication

    • MIFEPRISTONE (Generic for KORLYM)

    • QTY 1
    • 200 MG
    • Tablet

MIFEPRISTONE (mi FE pri stone) is used to end an early pregnancy. It works by decreasing levels of the hormone progesterone in the body, which stops the pregnancy from progressing.

MIFEPRISTONE (Generic for KORLYM) Lifestyle Interactions

  • Mifepristone 200mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Grapefruit juice or grapefruit-containing foods and Mifepristone together without talking to your health care provider. Side effects may get worse if you take these together. Contact your health care provider immediately if you experience nausea, vomiting, decreased appetite, headache, unusual tiredness or weakness, muscle weakness or cramps, palpitations or a change in your heartbeat (such as a fast or irregular heartbeat), or any other new or worsening side effects.
    • Notes for Professionals: Advise patients to avoid grapefruit juice while taking mifepristone due to increased mifepristone exposure. Mifepristone is a CYP3A4 substrate and grapefruit juice is a strong CYP3A4 inhibitor.

  • Mifepristone 200mg, Oral tablet

    • Interaction: Marijuana
    • Severity: Moderate
    • Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.
    • Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with mifepristone. Mifepristone is an inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with mifepristone, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.